Xichun Hu

机构：Shanghai Medical College of Fudan University, Fudan University Shanghai Cancer Center · ORCID：0000-0002-2157-2695

发表论文 20 篇 · 总被引 628 次 · h-index 8

代表论文

• Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer (2024 · New England Journal of Medicine · 被引 440)
• Efficacy and safety of mecapegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer: a randomized, multicenter, active-controlled phase III trial (2019 · Annals of Translational Medicine · 被引 36)
• Advantages with prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy: an open-label, randomized, multicenter phase III study (2017 · Breast Cancer Research and Treatment · 被引 34)
• Antiemetic therapy in Asia Pacific countries for patients receiving moderately and highly emetogenic chemotherapy—a descriptive analysis of practice patterns, antiemetic quality of care, and use of antiemetic guidelines (2014 · Supportive Care in Cancer · 被引 31)
• A randomized multicenter phase II trial of mecapegfilgrastim single administration versus granulocyte colony-stimulating growth factor on treating chemotherapy-induced neutropenia in breast cancer patients (2019 · Annals of Translational Medicine · 被引 20)
• The first-in-class bispecific antibody IBI318 (LY3434172) targeting PD-1 and PD-L1 in patients with advanced tumors: a phase Ia/Ib study (2024 · Journal of Hematology & Oncology · 被引 19)